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Introduction
Pulmonary tuberculosis (TB) represents an important
worldwide health problem. It has been reported by the
World Health Organization that one person in the world
becomes infected every second, and that one third of the
entire population of the world is now infected 1.  The
World Health Organization also estimates that in the
next decade, 300 million more people will be infected,
90 million people will develop the disease, and 30
million people will die from it1. 
The National Tuberculosis Control Programme in
Malaysia was introduced in 19612.  This has led to a
significant reduction in mortality such that diseases
caused by mycobacterium tuberculosis (MTB) are no
longer one of the 10 major causes of death 3.  In terms of
treatment, short course chemotherapy containing
rifampicin and isoniazid in combination has proved to
be highly effective in eradicating diseases but not
without the side effects of drug induced hepatitis. The
exact mechanism of drug induced hepatitis is still
unclear. The reported of incidence of hepatotoxic
reactions during anti tuberculosis treatment varies with
studies in Asia reporting higher risk of hepatitis (11.5%)
than the West (4.28%) 5.
The reasons for the higher incidence of hepatitis in
developing countries are unclear but prevalent viral
hepatitis has been suggested as a potential cause 6.
Several other risk factors have also been suggested such
as advanced age 7, sex 8, poor nutritional status 9, liver
disease 10, inappropriate use of drugs, chronic infections,
hepatitis B virus (HBV) carrier status 11, acetylator status12
and high alcohol intake8.  We report the findings of a
prospective survey to study the roles of some of these
factors in the development of anti tuberculosis drug
induced hepatitis among our patients receiving short
course anti-tuberculous chemotherapy at our chest
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clinic in Hospital Tengku Ampuan Afzan (HTAA),
Kuantan, Pahang.
Materials and Methods
We conducted a prospective survey between January
2000 and March 2001 on consecutive TB cases that had
developed icteric hepatitis whilst taking anti
tuberculosis treatment. All the patients were registered
at the chest clinic of HTAA and were admitted for
hepatitis. 
Diagnosis of drug-induced hepatitis was made based on
the presence of all the following criteria:
1. Clinical features of icteric hepatitis (anorexia, nausea
and jaundice).
2. Elevation of serum aspartate aminotransferase (AST)
and alanine aminotransferase (ALT) above 200U/l
(five times the upper limit of normal value) at the
time of admission.
3. Serum total bilirubin of more than 34.2 micromol/l.
4. Absence of serological evidence of an acute
infection with hepatitis A, B or C. IgM anti-hepatitis
A virus (HAV) antibody for acute hepatitis A
infection was done using enzyme linked
immunosorbent assay at a local private laboratory
(BP Lab). Hepatitis B surface antigen (HbsAg) and
anti-hepatitis C virus (HCV) antibody for hepatitis B
and C respectively were done at HTAA. A patient
known to be positive for HbsAg for at least 6 months
was regarded a HBV carrier. Otherwise IgM anti-
hepatitis B core antigen (IgM anti-HBc) was
requested to distinguish an acute infection (positive
IgM anti-HBc) from a chronic one. Any patient who
had positive anti HCV antibody test was excluded
from the study.
Drug regimens used on the patients were as follows:
(Streptomycin:S, Isoniazid:H, Rifampicin:R,
Pyrazinamide:Z and Ethambutol:E)
1. 2SHRZE/4RH2
2. 2SHRZ/4SRH2
3. 2HRZE/4RH2
4. 2HRZ/4RH2
Dosages of the drugs were calculated in relation to the
weight of the patients as follows:
1. Streptomycin: 15mg/kg
2. Rifampicin: 10mg/kg
3. Isoniazid: 5mg/kg
4. Ethambutol: 20mg/kg
5. Pyrazinamide: 25mg/kg
Details of patients' demographics were taken from the
case notes or during the interview. Treatment regimens,
doses, duration, alcohol intake, chronic Hepatitis B
carrier status, previous anti HCV antibody test, HIV
status and severity of chest radiograph (CXR) were also
noted. Significant alcohol intake was defined as
consumption of more than 6 units of alcohol daily for
more than six months. The CXR severity was classified
using the following criteria:
1. Minimal disease.
Slight lesions without demonstrable cavitation confined
to a small part of one or both lungs. The total extent of
the lesions shall not exceed the equivalent of the volume
of the lung tissue which lies above the second
costochondral junction or the spine of the fourth or the
body of the fifth thoracic vertebrae on one side
regardless of distribution.
2. Moderately advanced disease.
One or both lungs may be involved but the extent of the
lesions shall not exceed the following limits:
i. Slight disseminated lesions, which may extend
through not more than the volume of one lung or the
equivalent in both lungs
ii. Dense confluent lesions which may extend through
not more than the equivalent of one third the
volume of one lung and
iii. Total diameter of cavities is less than 4cms
3. Advanced disease is a lesion more extensive than in
moderately advanced disease.  All the CXRs were
assessed and graded by the first author. The duration of
treatment in days before the development of drug
induced hepatitis was also noted. During admission, all
the TB drugs were stopped and serial liver function tests
(LFTS) were done. Once normalization was noted,
chemotherapy was recommenced with S and E and drug
challenge was done sequentially with R, H and Z. The
offending drug if proven would then be gradually
introduced to the regime starting at the lowest dose and
gradually increasing to the dose calculated according to
the patient's weight. Failing this, an alternative regime
was used excluding the offending drug. There were two
patients who required an alternative regimen (HZE) as
reintroduction of rifampicin caused recurrence of
hepatitis.
A total of 30 patients from the chest clinic register agreed
to be controls.  They had all been treated with anti
tuberculous chemotherapy during the study period
without hepatotoxicity and had also agreed to answer
the preset questionnaires and agreed to blood taking. 
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Cases (n=14) Controls (n=30) P value
Mean age (SD) 47 (14.1) 41.9 (13.5) NS
M/F ratio 2.5:1 2.7:1 NS
Mean BMI (SD) 22.6  (2.1) 24.2   (1.5) 0.008
Ethnic group
Malay 11 24 NS
Chinese 3 5 NS
Indian 0 1 NS
BMI= body mass index, M/F= male/female, SD=standard deviation.
Table I: Age, male/female ratio and body mass index of the cases and controls
Cases (n=14) Controls (n=30) P value
Total bilirubin (g/L) 7.6 (3.4) 7.6 (2.6) NS
ALT (U/L) 21.5 (8.4) 17.7 (5.7) NS
AST (U/L) 19.7 (7.1) 17.3 (6.2) NS
Albumin (g/L) 33.0 (5.9) 35.8 (2.9) P<0.005
Globulin (g/L) 38.6 (5.8) 33.8 (4.5) P<0.04
Total bilirubin= total serum bilirubin, ALT=alanine transferase, AST=aspartate transferase, Alk Phosphatase=alkaline
phosphatase, Albumin= serum albumin, Globulin=serum globulin.
Table II: Mean (SD) of liver function tests results pre anti-tuberculous chemotherapy
Cases and controls were compared using t test and Chi
Square test for continous and categorical variables
respectively. Corrrelation was done using Pearson
correlation test and multiple regression analysis was
used to identify the factors that were significant in the
severity of hepatitis.
Results
There were 14 patients who developed anti tuberculous
drug induced hepatitis over the 15 months study period.
The cases and controls were compared (Table I) in
terms of age, male to female ratio and body mass index
(BMI) calculated from height (in metres) and weight (in
kilogram). The mean age was higher among the cases
but this was not significant. The male to female ratio and
mean BMI were lower in cases but only the latter was
significant (P<0.008). Base line liver function tests
revealed lower mean serum albumin (P<0.005) and
higher mean serum globulin (P<0.04) among cases
compared to controls (Table II). Both cases and controls
used similar treatment regimen (Table III).  The latency
period between the start of treatment and development
of hepatitis varied from 28 days to 77 days with mean of
53 (13.7) days.
During the acute episode of drug induced hepatitis,
serum total bilirubin, ALT and AST rose significantly but
serum albumin was somewhat reduced (Table IV).
Serum globulin remained unchanged. All cases in the
study were jaundiced and were admitted for
observation. One patient developed severe hepatic
failure and died despite stopping all anti tuberculosis
drugs. All other patients were successfully treated
conservatively and recommenced on similar drug
regimes except in two patients who required HZE.
Among the risk factors studied (Table V) we found that
HBsAg was more prevalent among the cases. The other
risk factors were not significantly different between the
two groups. 
We performed a multiple regression test to see if the
level of serum urea and creatinine (during acute
hepatitis), pretreatment albumin and globulin were
significant in the severity of hepatitis (by the level of
AST).  Using enter and remove method, none of the
factors above was significantly linked to the severity of
hepatitis. There was also no difference in the level of
elevated serum transaminases between males and
females in the cases. There was a single (7.1%) mortality
due to fulminant hepatitis within the period of study.
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Regimen* Cases (n=14) Controls (n=30) P value
2HRZE/4R2H2 11 18 NS
2SHRZ/4R2H2 1 9 NS
2HRZ/4R2H2 0 3 NS
2SHRZE/4R2H2 2 0 NS
* See text for details of drug regimens.
Table III: Drug regimens used in cases and controls
Cases (n=14)
Total bilirubin (g/L) 62.1 (17.4)
ALT (U/L) 291.6 (21.6)
AST (U/L) 280.1 (16.5)
Albumin (g/L) 30.4   (6.2)
Globulin (g/L) 38.8   (6.3)
*all results are expressed as mean (SD)
Table IV: Liver function test results* among cases during admission for hepatotoxicity
Cases (n=14) Controls (n=30) P value
High alcohol intake* 2 2 NS
HBV carrier* 4 1 0.014
HIV+ve 3 1 NS
Severe CXR lesions* 4 8 NS
*see main text for further explanation. 
HIV+ve=positive HIV test
Table V: Potential risk factors in cases and controls.
Discussion
The development of anti tuberculosis drug induced
hepatitis is of great significance because it necessitates
cessation of therapy. Occasionally different regimen
may have to be initiated if the patients are intolerant of
the drugs.  Steele et al reported in a meta-analysis13 that
isoniazid and rifampicin given together produce
hepatotoxicity more often than when isonizid is given
alone. Wide variations in the incidence of hepatotoxic
reactions have been reported4,5.  The relatively high
incidence of hepatotoxicty in developing countries have
been attributed to various factors such as old age, higher
alcohol intake, malnutrition, intestinal parasitism, past
history of jaundice, chronic liver disease, indiscriminate
use of drugs and viral hepatitis14.  There is no consensus
as to which of these factors are involved either singly or
in combination in causing hepatitis. We need to identify
the group with risk factors as close monitoring can be
done to avoid severe drug induced hepatitis.
Previous studies7 have shown that older age was
significantly more frequent in the group that developed
hepatitis.  Our study demonstrated a similar trend in that
the mean age was higher in the cases compared to
controls but the difference was not significant.  We
attributed this to our small sample size. Some studies8
have also shown female preponderance in the hepatitis
group and similarly this trend was noticeable in our
study.
Poor nutritional status has been found to be one of the
risk factors for hepatotoxicity9.  Our study has shown
that both BMI (P<0.05) and serum albumin (P<0.005)
were lower in cases compared to controls but these
13/RISK  10/04/2004  3:34SAN  Page 75
ORIGINAL ARTICLE
76 Med J Malaysia Vol 59 No 1 March 2004
values were not sufficiently low to be labelled as
malnutrition.
High alcohol intake8 was not found to be significantly
different between the two groups although this has been
shown to be a significant risk factor.  We are not certain
whether or not denial among our patients was in any
way contributory to this finding.  There was no
significant difference between the severity of CXR and
the regimens used in both the cases and the controls.
Previous studies 13 have shown that isoniazid and
rifampicin given together cause hepatotoxicity more
frequently than isoniazid alone. The addition of
pyrazinamide has not been shown to alter the rates of
hepatotoxicity significantly5.
Our study has also noted significant difference in the
number of HB s Ag positive among cases compared to
controls.  Earlier studies have shown that HB s Ag
positivity11 was significantly associated with the
hepatotoxicity, although there was no difference in the
level of pretreatment liver transaminases between the
two groups in our study.   Pretreatment albumin
however was lower among cases.  There was a
significant positive correlation between the level of
serum urea and the level of serum transaminases during
acute drug induced hepatitis. This was probably a
reflection of the severity of nausea and vomiting in
severe hepatitis.  The patients as a consequence were
deprived of adequate oral intake and this was reflected
by higher serum urea and creatinine in severe hepatitis.
Our study has an obvious limitation in terms of
numbers. Nevertheless the findings are consistent with
the findings from previous studies.  A bigger prospective
study is required to validate these findings within the
context of Malaysia.  In conclusion, patients who
developed tuberculosis drug induced hepatitis at our
chest clinic were more likely to have lower BMI, lower
pretreatment serum albumin and higher serum globulin.
The number of chronic HBV carriers was also
significantly higher.  We also found that the higher the
level of liver transaminases during an acute drug
induced hepatitis the higher the level of serum urea and
creatinine.
Conclusion
Our study findings demonstrate that EUGIE performed
for appropriate indications yields more significant
findings.  Standard guidelines should be utilised to
improve or maintain standards of endoscopic services in
ensuring cost-benefit and quality assurance. Future
research should address the issue of the outcome of
patients with indications labelled inappropriate because
endoscopies labelled inappropriate were found to be
associated with occasional important endoscopic
lesions.
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